Meeting Register Page

Designing, conducting and applying results from patient preference studies: the PREFER framework
Including patient preferences in decision-making is an important part of patient-focused drug development. The lack of a clear, practical framework for measuring patient preferences was one of stakeholders' main concerns brought up during PREFER’s initial research and more recently at the DIA-Prefer workshop. Thus, PREFER developed and sent the PREFER framework for patient preferences to the EMA and HTA bodies under the methods qualification procedure. The public consultation on this procedure likely will begin in late summer 2021.

1. Introduction to the PREFER framework & what we’d like this to achieve, 5 mins, Conny Berlin, IMI PREFER Project Leader & Global Head, Quantitative Safety and Epidemiology
Novartis Pharma AG, Switzerland

2. How the PREFER framework addresses the study purpose; study organization, design & conduct, 15 mins, Kristin Bullok, Benefit-Risk Management Scientist, Global Patient Safety; Eli Lilly and Company, United States

3. Points to consider for method selection, 15 mins, Brett Haber, Senior Director, Patient Preference Elicitation Pfizer, United States

4. PREFER framework continued: application of preference data to inform regulatory decision-making, 15 mins, Bennett Levitan, Senior Director, Benefit-Risk Assessment, Global R&D Epidemiology; Janssen Research & Development, United States

5. PREFER framework continued further: application of preference data to inform HTA decision-making, 15 mins, Irina Cleemput, Scientific Programme Director Belgian Health Care Knowledge Centre (KCE), Belgium

6. Q&A, 25 mins, Conny Berlin (chair)

PREFER only collects information necessary to fulfill its project objectives on a voluntary, opt-in basis in accordance with applicable laws and regulations. By submitting this form, you confirm that you have read and agree with the data protection measures outlined in the PREFER data protection notice:
Registration is closed.